ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Insulin glulisine: Drug information

Insulin glulisine: Drug information
(For additional information see "Insulin glulisine: Patient drug information" and see "Insulin glulisine: Pediatric drug information")

For abbreviations, symbols, and age group definitions used in Lexicomp (show table)
Brand Names: US
  • Apidra;
  • Apidra SoloStar
Brand Names: Canada
  • Apidra;
  • Apidra SoloStar
Pharmacologic Category
  • Insulin, Rapid-Acting
Dosing: Adult

Note: Insulin glulisine is a rapid-acting insulin analog. Insulin requirements vary between patients; monitor glucose levels frequently and individualize dose.

Diabetes mellitus, type 1, treatment

Diabetes mellitus, type 1, treatment:

Note: Insulin glulisine must be used concomitantly with intermediate- or long-acting insulin (ie, multiple daily injection regimen) or in a continuous subcutaneous insulin infusion device. The total daily doses (TDD) presented below are expressed as the total units/kg/day of all insulin formulations combined.

General insulin dosing:

Initial TDD: SUBQ: ~0.4 to 0.5 units/kg/day; conservative initial doses of 0.2 to 0.4 units/kg/day may be considered to avoid the potential for hypoglycemia; higher initial doses may be required in patients with obesity, or who are sedentary or presenting with ketoacidosis (AACE/ACE [Handelsman 2015]; ADA 2022).

Usual TDD maintenance range: SUBQ: 0.4 to 1 units/kg/day in divided doses (ADA 2022).

Division of TDD (multiple daily injections):

Basal insulin: Generally, 40% to 50% of the TDD is given as basal insulin (intermediate- or long-acting) in 1 to 2 daily injections (AACE/ACE [Handelsman 2015]; ADA 2022).

Prandial insulin: The remaining portion (ie, 50% to 60%) of the TDD is then divided and administered before, at, or just after mealtimes depending on the formulation (eg, short-, rapid-, ultra-rapid acting) (AACE/ACE [Handelsman 2015]; ADA 2022).

Dosage adjustment: Dosage must be titrated to achieve glucose control and avoid hypoglycemia. Adjust dose to maintain premeal and bedtime glucose in target range. Since combinations of agents are frequently used, dosage adjustment must address the individual component of the insulin regimen which most directly influences the blood glucose value in question, based on the known onset and duration of the insulin component.

Diabetes mellitus, type 2, treatment

Diabetes mellitus, type 2, treatment:

Note: May be used if glycemic targets are not met despite adequately titrated basal insulin (eg, fasting glucose levels not at goal, basal insulin dose >0.5 units/kg/day) (ADA 2022). For regimens containing basal and prandial insulin, consider discontinuing noninsulin agents other than metformin, glucagon-like peptide-1 receptor agonists, and sodium-glucose cotransporter-2 inhibitors (ADA 2022; ADA/EASD [Davies 2018]).

Initial:

Note: Prandial insulin regimens are typically initiated as one daily injection administered before the largest meal; additional mealtime injections may be added based on results of glucose monitoring. In patients with HbA1c <8% when prandial insulin is initiated, consider reducing the basal insulin daily dose by 4 units/day or by 10% (AACE/ACE [Garber 2020]; ADA 2022).

SUBQ: 4 to 6 units or 10% of the basal insulin dose (AACE/ACE [Garber 2020]; ADA 2022; Wexler 2022).

Dosage adjustment: Note: Individualize dosage adjustments based on patient-specific factors (eg, glucose levels, carbohydrate intake) (ADA 2022).

For persistently elevated glucose levels: SUBQ: Consider intensification of dietary modifications and/or increasing the corresponding mealtime dose(s) by 1 to 2 units or by 10% to 15% every 3 days to achieve glycemic targets while avoiding hypoglycemia (ADA 2022; Wexler 2022). Note: More aggressive dose increases (eg, by ≥5 units) may be required in patients already taking >20 units/dose of insulin glulisine (Wexler 2022).

For hypoglycemia: SUBQ: For unexplained mild to moderate hypoglycemia, consider decreasing the corresponding mealtime dose(s) by 10% to 20% (ADA 2022); for hypoglycemia requiring assistance from another person or blood glucose <40 mg/dL, consider decreasing the corresponding mealtime dose(s) by 20% to 50% (AACE/ACE [Garber 2020]; Wexler 2022).

Patients with diabetes receiving enteral feedings

Patients with diabetes receiving enteral feedings: Note: TDD of insulin is divided into a basal component (intermediate- or long-acting insulin) and nutritional and correctional components (regular insulin or rapid-acting insulins).

Nutritional: SUBQ : 1 unit of insulin glulisine per 10 to 15 g of carbohydrate prior to each bolus feeding; in patients receiving continuous feeds, administer every 4 hours based on the amount of carbohydrate administered over each 4-hour period (ADA 2022; ES [Umpierrez 2012]).

Correctional: SUBQ : Administer correctional insulin as needed prior to each feeding (for bolus feeds) or every 4 hours (for continuous feeds) (ADA 2022). Dosing is individualized; one example of an empiric correctional dose is 1 to 2 units per 40 to 50 mg/dL above target glucose level; patients with known insulin resistance or who are receiving glucocorticoids may require higher correctional doses (eg, 4 units per 50 mg/dL above target glucose level) (Clement 2004; ES [Umpierrez 2012]; Gianchandani 2020; Inzucchi 2011; Magaji 2011).

Patients with diabetes undergoing surgery and using an insulin pump

Patients with diabetes undergoing surgery and using an insulin pump: SUBQ: For short procedures (eg, <2 hours), continue the usual pump “basal” insulin infusion rate, with or without a temporary 20% to 40% rate reduction, on the morning of the procedure. For long and complex procedures, consider transitioning from the insulin pump to an IV regular insulin infusion perioperatively (ADA 2022; Leung 2017).

Diabetic ketoacidosis, mild to moderate, uncomplicated

Diabetic ketoacidosis, mild to moderate, uncomplicated (alternative agent) (off-label use):

Note: SUBQ insulin glulisine may be used as an alternative to IV regular insulin in patients in whom management of diabetic ketoacidosis (DKA) outside of a critical care area is appropriate. IV regular insulin (preferred over IV rapid-acting insulin analogs) should be used in patients with severe DKA, evidence of hyperosmolar hyperglycemic state (eg, altered mental status), persistent hypotension, or other critical illness, as well as during pregnancy (Cardoso 2017; Kitabchi 2009). Begin correction of fluid deficits, if present. If serum potassium is <3.3 mEq/L on initial presentation, delay insulin administration until serum potassium reaches ≥3.3 mEq/L. Address other electrolyte abnormalities, as needed, during insulin administration (Kitabchi 2009). In patients with initial serum glucose <250 mg/dL, initiate dextrose-containing IV fluids at the time of insulin initiation (Rawla 2017). An example of a dosing regimen is as follows; refer to institutional protocols:

1-hour interval dosing: SUBQ: 0.3 units/kg once, followed by 0.1 units/kg every hour until blood glucose <250 mg/dL, then decrease to 0.05 units/kg every hour until resolution of ketoacidosis. May increase dose (eg, by double) if serum glucose does not decrease by ~50 to 75 mg/dL in the first hour (Hirsch 2021; Kitabchi 2009).

2-hour interval dosing: SUBQ: 0.3 units/kg once, followed by 0.2 units/kg 1 hour later and then every 2 hours thereafter until blood glucose <250 mg/dL, then decrease to 0.1 units/kg every 2 hours until resolution of ketoacidosis. May increase dose (eg, by double) if serum glucose does not decrease by ~50 to 75 mg/dL in the first hour (Hirsch 2021; Kitabchi 2009).

Hyperglycemia, hospitalized patients

Hyperglycemia, hospitalized patients (off-label use):

Note: For use in patients with persistent hyperglycemia (eg, blood glucose ≥140 to 180 mg/dL for >12 to 24 hours) with or without a history of diabetes; use of institution-specific protocols to achieve glycemic targets and minimize hypoglycemia is encouraged (ADA 2022; ES [Umpierrez 2012]; SCCM [Jacobi 2012]).

Correctional insulin:

Note: For use in addition to scheduled basal and nutritional insulin to achieve glycemic targets; prolonged use of correctional insulin without basal insulin is discouraged (ADA 2022; ADA/AACE [Moghissi 2009]).

SUBQ: Refer to institution-specific protocols; one example of an empiric correctional dose is 1 to 2 units per 40 to 50 mg/dL above target glucose level; dose is typically administered with meals (or bolus feeds) or every 4 hours (if NPO or receiving continuous feeds); patients with known insulin resistance or who are receiving glucocorticoids may require higher correctional doses (eg, 4 units per 50 mg/dL above target glucose level) (ADA 2022; Clement 2004; ES [Umpierrez 2012]; Gianchandani 2020; Inzucchi 2011; Magaji 2011).

Nutritional insulin:

Initial daily dosage:

Patients not receiving nutritional insulin prior to hospitalization:

Patients eating meals: SUBQ: 0.03 to 0.1 units/kg/meal administered with or just after meals (ADA 2022; ES [Umpierrez 2012]). Note: Dose is individualized; consider doses at the lower end of this range in older patients and in those with renal impairment; consider doses at the higher end of this range in patients receiving glucocorticoids (ES [Umpierrez 2012]).

Patients receiving enteral feeds: SUBQ: 1 unit of insulin glulisine per 10 to 15 g of carbohydrate prior to each bolus feeding; in patients receiving continuous feeds, administer every 4 hours based on the amount of carbohydrate administered over each 4-hour period (ADA 2022; ES [Umpierrez 2012]).

Patients receiving nutritional insulin prior to hospitalization: SUBQ: Continue the prehospitalization nutritional insulin dose; an empiric 25% to 50% dose reduction may be considered in patients with impaired renal function, poor nutritional intake, or admission glucose levels <100 mg/dL; higher doses may be required in patients receiving glucocorticoids (ADA 2022; ES [Umpierrez 2012]; Inzucchi 2011).

Dosage adjustment: Adjust daily dose by 10% to 20% every 2 to 3 days to achieve glycemic targets. Consider reducing dosage for glucose levels <100 mg/dL to avoid hypoglycemia; in patients with glucose levels <40 mg/dL, larger dose reductions (eg, by 20% to 40%) may be needed (AACE/ACE [Garber 2020]; ADA/AACE [Moghissi 2009]).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling; insulin requirements may be reduced due to changes in insulin clearance or metabolism; monitor blood glucose closely.

Dosing: Hepatic Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling; insulin requirements may be reduced due to changes in insulin clearance or metabolism; monitor blood glucose closely.

Dosing: Older Adult

Refer to adult dosing; avoid insulin regimens that only use short- or rapid-acting insulins dosed based on current blood glucose levels in the absence of basal or long-acting insulin (Ref).

Dosing: Pediatric

(For additional information see "Insulin glulisine: Pediatric drug information")

Insulin glulisine is a rapid-acting insulin analog. Insulin doses should be individualized based on patient needs; adjustments may be necessary with changes in physical activity, meal patterns, acute illness, or with changes in renal or hepatic function. Insulin requirements vary dramatically between patients and dictates frequent monitoring and close medical supervision. Insulin regimens vary widely by region, practice, and institution; consult institution-specific guidelines.

Diabetes mellitus, type 1

Diabetes mellitus, type 1: Children and Adolescents: Note: Insulin glulisine is generally used concomitantly with intermediate- or long-acting insulin (ie, multiple daily injection regimen) or in a continuous subcutaneous infusion pump. The daily doses presented are expressed as the total units/kg/day of all insulin formulations combined.

General insulin dosing:

Initial total daily insulin: SubQ: Initial: 0.4 to 0.5 units/kg/day in divided doses (AACE/ACE [Handelsman 2015]; ADA 2020); usual range: 0.4 to 1 units/kg/day in divided doses (AACE/ACE [Handelsman 2015]; ADA 2020; Silverstein 2005); lower doses (0.25 units/kg/day) may be used, especially in young children, to avoid potential hypoglycemia (Beck 2015); higher doses may be necessary for some patients (eg, obese, concomitant steroids, puberty, sedentary lifestyle, following diabetic ketoacidosis presentation) (AACE/ACE [Handelsman 2015]; ADA 2020; Silverstein 2005).

Usual total daily maintenance range: SubQ: Doses must be individualized; however, an estimate can be determined based on phase of diabetes and level of maturity (ISPAD [Danne 2018]; ISPAD [Sundberg 2017]).

Partial remission phase (Honeymoon phase): <0.5 units/kg/day.

Prepubertal children (not in partial remission):

Infants ≥6 months and Children ≤6 years: 0.4 to 0.8 units/kg/day.

Children ≥7 years: 0.7 to 1 units/kg/day.

Pubescent Children and Adolescents: During puberty, requirements may substantially increase to >1 unit/kg/day and in some cases up to 2 units/kg/day.

Division of daily insulin requirement (multiple daily injections):

Basal insulin: Generally, ~30% to 50% of the total daily insulin is given as basal insulin (intermediate- or long-acting) in 1 to 2 daily injections (AACE/ACE [Handelsman 2015]; ADA 2020; ISPAD [Danne 2018]; Peters 2013).

Prandial insulin: The remaining portion of the total daily dose is then divided and administered before or at mealtimes (depending on the formulation) as a rapid-acting (eg, aspart, glulisine, lispro) or short-acting (regular). In most type 1 patients, the use of a rapid-acting insulin analog is preferred over regular insulin to reduce hypoglycemia risk (AACE/ACE [Handelsman 2015]; ADA 2020; ADA [Chiang 2014]; ISPAD [Danne 2018]).

Dosage titration: Treatment and monitoring regimens must be individualized to maintain premeal and bedtime glucose in target range; titrate dose to achieve glucose control and avoid hypoglycemia. Since combinations of agents are frequently used, dosage adjustment must address the individual component of the insulin regimen which most directly influences the blood glucose value in question, based on the known onset and duration of the insulin component.

Surgical patients (ISPAD [Jefferies 2018]): Note: Diabetic patients should be scheduled as the first case of the day.

Minor surgeries:

Morning procedure: Omit rapid-acting insulin (eg, aspart, glulisine, lispro) until after surgery and patient is able to eat unless it is needed to correct significant hyperglycemia and/or significant ketone (>0.1 mmol/mol) production is present.

Afternoon procedure: If allowed to eat breakfast, administer the usual dose of rapid-acting insulin (eg, aspart, glulisine, lispro) with breakfast.

Postprocedure: Once normal oral intake is achieved, resume usual insulin regimen; monitor closely; insulin requirement may be higher due to changes related to surgery (ie, postoperative stress, medication changes, inactivity).

Major surgeries:

Evening prior to surgery: Administer the usual evening and/or bedtime insulin(s); patients on continuous subcutaneous insulin infusion (CSII) may continue normal insulin basal rates overnight; if there is a concern for hypoglycemia, basal rate may be reduced by 20% at ~3 am.

Morning of surgery: Omit morning insulin (short- and long-acting) and start IV insulin (regular) infusion and IV dextrose at least 2 hours prior to surgery; patients on CSII should discontinue CSII when IV insulin infusion is started.

Postprocedure: Once normal oral intake is achieved, resume usual insulin regimen; monitor closely; insulin requirement may be higher due to changes related to surgery (ie, postoperative stress, medication changes, inactivity).

Diabetes mellitus, type 2

Diabetes mellitus, type 2: Children ≥10 years and Adolescents: SubQ: The goal of therapy is to achieve an HbA1c <7% as quickly as possible using the safe titration of medications. Initial therapy in metabolically unstable patients (eg, plasma glucose ≥250 mg/dL, HbA1c >8.5%, symptoms excluding acidosis) may include once-daily intermediate-acting insulin or basal insulin in combination with lifestyle changes and metformin. In patients who fail to achieve glycemic goals with metformin and basal insulin, may consider initiating prandial insulin (regular insulin or rapid-acting insulin) and titrate to achieve goals. Once initial goal reached, insulin should be slowly tapered over 2 to 6 weeks by decreasing the insulin dose by 10% to 30% every few days and the patient transitioned to lowest effective doses or metformin monotherapy if able (AAP [Copeland 2013]; ADA 2020; ADA [Arslanian 2018]; ISPAD [Zeitler 2018]). Note: Patients who are ketotic or present with ketoacidosis require aggressive management.

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Pediatric

There are no dosage adjustments provided in manufacturer's labeling; insulin requirements are reduced due to changes in insulin clearance or metabolism; monitor blood glucose closely.

Dosing: Hepatic Impairment: Pediatric

There are no dosage adjustments provided in manufacturer's labeling; insulin requirements may be reduced due to changes in insulin clearance or metabolism; monitor blood glucose closely.

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reported adverse reactions are for children, adolescents, and adults unless otherwise specified.

>10%:

Endocrine & metabolic: Severe hypoglycemia (7% to 16%)

Respiratory: Nasopharyngitis (8% to 11%), upper respiratory tract infection (7% to 11%)

1% to 10%:

Cardiovascular: Hypertension (adults: 4%), peripheral edema (adults: 8%)

Hypersensitivity: Hypersensitivity reaction (4%)

Infection: Influenza (4% to 6%)

Local: Infusion site reaction (10%)

Nervous system: Headache (children and adolescents: 7%), hypoglycemic seizure (children and adolescents: 6%)

Neuromuscular & skeletal: Arthralgia (adults: 6%)

<1%: Local: Catheter complication

Frequency not defined: Immunologic: Antibody development (no effect on drug efficacy)

Postmarketing: Endocrine & metabolic: Amyloidosis (cutaneous at injection site)

Contraindications

Hypersensitivity to insulin glulisine or any component of the formulation; during episodes of hypoglycemia

Warnings/Precautions

Concerns related to adverse effects:

• Glycemic control: Hyper- or hypoglycemia may result from changes in insulin strength, manufacturer, type, and/or administration method. The most common adverse effect of insulin is hypoglycemia. The timing of hypoglycemia differs among various insulin formulations. Hypoglycemia may result from changes in meal pattern (eg, macronutrient content, timing of meals), changes in the level of physical activity, increased work or exercise without eating, or changes to coadministered medications. Use of long-acting insulin preparations (eg, insulin degludec, insulin detemir, insulin glargine) may delay recovery from hypoglycemia. Patients with renal or hepatic impairment may be at a higher risk. Symptoms differ in patients and may change over time in the same patient; awareness may be less pronounced in those with long-standing diabetes, diabetic nerve disease, patients taking beta-blockers, or in those who experience recurrent hypoglycemia. Profound and prolonged episodes of hypoglycemia may result in convulsions, unconsciousness, temporary or permanent brain damage, or even death. Insulin requirements may be altered during illness, emotional disturbances, or other stressors. Instruct patients to use caution with ethanol; may increase risk of hypoglycemia.

• Hypersensitivity: Hypersensitivity reactions, including life-threatening reactions (anaphylaxis), can occur with insulin glulisine; discontinue, treat per standard of care, and monitor until signs and symptoms resolve.

• Hypokalemia: Insulin (especially IV insulin) causes a shift of potassium from the extracellular space to the intracellular space, possibly producing hypokalemia. If left untreated, hypokalemia may result in respiratory paralysis, ventricular arrhythmia and even death. Use with caution in patients at risk for hypokalemia (eg, loop diuretic use). Monitor serum potassium frequently with IV use and supplement potassium when necessary.

Disease-related concerns:

• Bariatric surgery:

– Type 2 diabetes, hypoglycemia: Closely monitor insulin dose requirement throughout active weight loss with a goal of eliminating antidiabetic therapy or transitioning to agents without hypoglycemic potential; hypoglycemia after gastric bypass, sleeve gastrectomy, and gastric band may occur (Mechanick 2020). Insulin secretion and sensitivity may be partially or completely restored after these procedures (Korner 2009; Peterli 2012). Rates and timing of type 2 diabetes improvement and resolution vary widely by patient. Insulin dose reduction of ≥75% has been suggested after gastric bypass for patients without severe beta-cell failure (fasting c-peptide <0.3 nmol/L) (Cruijsen 2014). Avoid the use of bolus insulin injections or dose conservatively with close clinical monitoring in the early phases after surgery.

– Weight gain: Insulin therapy is preferred if antidiabetic therapy is required during the perioperative period (Mechanick 2019). Evaluate risk versus benefit of long-term post-operative use and consider alternative therapy due to potential for insulin-induced weight gain (Apovian 2015).

• Cardiac disease: Concurrent use with peroxisome proliferator-activated receptor (PPAR)-gamma agonists, including thiazolidinediones, may cause dose-related fluid retention and lead to or exacerbate heart failure (HF), particularly when used in combination with insulin. If PPAR-gamma agonists are prescribed, monitor for signs and symptoms of HF. If HF develops, consider PPAR-gamma agonist dosage reduction or therapy discontinuation.

• Hepatic impairment: Use with caution in patients with hepatic impairment; may be at increased risk for hypoglycemia. Dosage requirements may be reduced, and patients may require more frequent dose adjustments and blood glucose monitoring.

• Renal impairment: Use with caution in patients with renal impairment; may be at increased risk for hypoglycemia. Dosage requirements may be reduced, and patients may require more frequent dose adjustments and blood glucose monitoring.

Special populations:

• Older adult: Use with caution in older adult patients; may be more at risk for hypoglycemia. Consider conservative initial dosing, dose increments, and maintenance dose.

• Hospitalized patients: Prolonged use of a sliding scale insulin regimen in the inpatient setting is strongly discouraged. In the critical care setting, continuous IV insulin infusion (insulin regular) has been shown to best achieve glycemic targets. In noncritically ill patients with either poor oral intake or taking nothing by mouth, basal insulin use is preferred, with correctional doses (insulin regular or rapid-acting insulin) as needed. In noncritically ill patients with adequate nutritional intake, a combination of basal insulin along with nutritional and correctional components (insulin regular or rapid-acting insulin) is preferred. An effective insulin regimen will achieve the goal glucose range without the risk of severe hypoglycemia). A blood glucose value <70 mg/dL should prompt a treatment regimen review and change, if necessary, to prevent further hypoglycemia (ADA 2022).

Dosage form specific issues:

• Multiple dose injection pens: According to the Centers for Disease Control and Prevention (CDC), pen-shaped injection devices should never be used for more than one person (even when the needle is changed) because of the risk of infection. The injection device should be clearly labeled with individual patient information to ensure that the correct pen is used (CDC 2012).

Other warnings/precautions:

• Continuous subcutaneous insulin infusion administration: May be administered via continuous subcutaneous insulin infusion; do not dilute or mix with other insulin formulations. Rule out external pump failure if unexplained hyperglycemia or ketosis occurs; temporary SUBQ insulin administration may be required until the problem is identified and corrected.

• IV administration: Insulin glulisine may be administered IV in selected clinical situations to control hyperglycemia; close monitoring of blood glucose and serum potassium as well as medical supervision is required.

• Patient education: Diabetes self-management education (DSME) is essential to maximize the effectiveness of therapy.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution, Injection:

Apidra: 100 units/mL (10 mL) [contains metacresol]

Solution Pen-injector, Subcutaneous:

Apidra SoloStar: 100 units/mL (3 mL) [contains metacresol]

Generic Equivalent Available: US

No

Pricing: US

Solution (Apidra Injection)

100 units/mL (per mL): $10.22

Solution Pen-injector (Apidra SoloStar Subcutaneous)

100 units/mL (per mL): $13.16

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution, Subcutaneous:

Apidra: 100 units/mL (10 mL) [contains metacresol]

Solution Cartridge, Subcutaneous:

Apidra: 100 units/mL (3 mL) [contains metacresol]

Solution Pen-injector, Subcutaneous:

Apidra SoloStar: 100 units/mL (3 mL) [contains metacresol]

Administration: Adult

Use only if solution is clear and colorless; do not use if solution contains particulate matter or is colored.

SUBQ administration: Insulin glulisine should be administered within 15 minutes before or within 20 minutes after starting a meal. Cold injections should be avoided. SUBQ administration is usually made into the thighs, arms, or abdomen; rotate injection sites within the same region to avoid lipodystrophy or localized cutaneous amyloidosis. Rotating from an injection site where lipodystrophy/cutaneous amyloidosis is present to an unaffected site may increase risk of hypoglycemia. Insulin glulisine from a vial may be mixed with insulin NPH only (do not mix with other types of insulin); insulin glulisine should be drawn into syringe first. Apidra SoloStar prefilled pens are designed to dial doses in 1-unit increments. Do not mix other insulin formulations with insulin glulisine contained in a cartridge or prefilled pen. For Apidra SoloStar pen, prime the needle before each injection with 2 units of insulin (use a new needle for each injection). Once injected, continue to depress the button until the dial has returned to 0 and for an additional 10 seconds. Then, remove the needle.

Continuous subcutaneous insulin infusion administration: Patients should be trained in the proper use of their external insulin pump and in intensive insulin therapy. Infusion sets, reservoirs, infusion set insertion sites, and the insulin in the reservoir should be changed every 48 hours or according to continuous SUBQ insulin infusion device user manual (whichever is shorter); rotate infusion sites. Do not dilute or mix other insulin formulations with insulin glulisine that is to be used in an external insulin pump.

IV administration: May be administered IV with close monitoring of blood glucose and serum potassium; appropriate medical supervision is required. Do not administer insulin mixtures intravenously.

IV infusions: To minimize insulin adsorption to plastic IV tubing: Although data is lacking regarding adsorption with insulin glulisine, insulin regular loss has been shown to occur by adsorption to plastic (ie, PVC, polyethylene, polyolefin, polypropylene) IV containers and tubing (Greenwood 2012; Hirsch 1977; Hirsch 1981; Rocchio 2013; Thompson 2012). Therefore, flush the IV tubing with a priming infusion of 20 mL from the insulin infusion, whenever a new IV tubing set is added to the insulin infusion container (SCCM [Jacobi 2012]; Thompson 2012).

Note: Also refer to institution-specific protocols where appropriate.

Because of insulin adsorption to plastic IV tubing or infusion bags, the actual amount of insulin being administered via IV infusion could be substantially less than the apparent amount. Therefore, adjustment of the IV infusion rate should be based on effect and not solely on the apparent insulin dose. The apparent dose may be used as a starting point for determining the subsequent SUBQ dosing regimen (Moghissi 2009); however, the transition to SUBQ administration requires continuous medical supervision, frequent monitoring of blood glucose, and careful adjustment of therapy. In addition, SUBQ insulin should be given 1 to 4 hours prior to the discontinuation of IV insulin to prevent hyperglycemia (Moghissi 2009).

Administration: Pediatric

Parenteral: Do not use if solution is viscous or cloudy; use only if clear and colorless with no visible particles.

SUBQ: Administer 15 minutes before meals or within 20 minutes after starting a meal. Cold injections should be avoided. SubQ administration is usually made into the subcutaneous fat of the thighs, arms, or abdomen; rotate injection sites within the same region to avoid lipodystrophy or localized cutaneous amyloidosis. Rotating from an injection site where lipodystrophy/cutaneous amyloidosis is present to an unaffected site may increase risk of hypoglycemia.

Prefilled pen: Apidra SoloSTAR prefilled pens will administer up to 80 units per injection in 1-unit increments. Prior to each injection, the needle must be primed with 2 units of insulin (use a new needle for each injection); see manufacturer's labeling for specific procedure. Once primed, set dial to the appropriate dose, insert needle into clean skin, and activate device by holding the button down; continue to hold the button until the dose dial has returned to 0 units. After the insulin is injected, hold the needle in the skin for 10 seconds after the dose dial has returned to 0 units to ensure the full dose has been administered. Do not rub the area. If dose is >80 units, >1 injection will be required; split dose and administer in multiple injections. Do not mix other insulin formulations with insulin glulisine contained in a prefilled pen.

Vial: Insulin glulisine from a vial may be mixed in the same syringe with NPH insulin; do not mix with other types of insulin. When mixing insulin glulisine with NPH insulin, insulin glulisine should be drawn into the syringe first. Use immediately after mixing.

Continuous SUBQ insulin infusion (CSII) (insulin pump): Do not use if solution is viscous or cloudy; use only if clear and colorless. Patients should be trained in the proper use of their external insulin pump and in intensive insulin therapy. Infusion sets, reservoirs, infusion set insertion sites and the insulin in the reservoir should be changed every 48 hours or according to CSII device user manual (whichever is shorter); rotate infusion sites. Do not dilute or mix other insulin formulations with insulin glulisine that is to be used in an external insulin pump.

IV: Insulin glulisine may be administered IV in selected clinical situations to control hyperglycemia. Closely monitor blood glucose and serum potassium; appropriate medical supervision is required. Further dilution required prior to administration; administer using PVC infusion bags into a dedicated infusion line (the use of other bags and tubing has not been studied). Do not administer insulin mixtures IV.

To minimize insulin adsorption to IV tubing: Although data is lacking regarding adsorption with insulin glulisine, insulin regular loss has been shown to occur by adsorption to plastic (ie, PVC, polyethylene, polyolefin, polypropylene) IV containers and tubing (Greenwood 2012; Hirsch 1977; Hirsch 1981; Rocchio 2013; Thompson 2012). Therefore, flush the IV tubing with a priming volume of 20 mL from the insulin infusion, whenever a new IV tubing set is added to the insulin infusion container (Jacobi 2012; Thompson 2012). Also refer to institution-specific protocols where appropriate.

Because of insulin adsorption to IV tubing or infusion bags, the actual amount of insulin being administered via IV infusion could be substantially less than the apparent amount. Therefore, adjustment of the IV infusion rate should be based on effect and not solely on the apparent insulin dose. The apparent dose may be used as a starting point for determining the subsequent SUBQ dosing regimen (Moghissi 2009); however, the transition to SubQ administration requires continuous medical supervision, frequent monitoring of blood glucose, and careful adjustment of therapy. In addition, SUBQ insulin should be given 1 to 4 hours prior to the discontinuation of IV insulin to prevent hyperglycemia (Moghissi 2009).

Use: Labeled Indications

Diabetes mellitus, types 1 and 2, treatment: Treatment of type 1 diabetes mellitus and type 2 diabetes mellitus to improve glycemic control

Use: Off-Label: Adult

Diabetic ketoacidosis, mild to moderate, uncomplicated; Hyperglycemia, hospitalized patients

Medication Safety Issues
Sound-alike/look-alike issues:

Apidra may be confused with Spiriva

Insulin glulisine may be confused with insulin glargine

High alert medication:

The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error. Due to the number of insulin preparations, it is essential to identify/clarify the type of insulin to be used.

Older Adult: High-Risk Medication:

Beers Criteria: Insulin (short- or rapid-acting insulin products used for sliding scale), is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older (independent of diagnosis or condition) due to higher risk of hypoglycemia associated with sliding scale insulin without improvements in hyperglycemia, regardless of care setting. Avoid insulin regimens that only use short- or rapid-acting insulins dosed based on current blood glucose levels in the absence of basal or long-acting insulin; recommendation does not apply to regimens containing basal or long-acting insulin (Beers Criteria [AGS 2023]).

Other safety concerns:

Cross-contamination may occur if insulin pens are shared among multiple patients. Steps should be taken to prohibit sharing of insulin pens.

Metabolism/Transport Effects

None known.

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.

Alpha-Glucosidase Inhibitors: May enhance the hypoglycemic effect of Insulins. Management: Consider a decrease in insulin dose when initiating therapy with an alpha-glucosidase inhibitor and monitor patients for hypoglycemia. Risk D: Consider therapy modification

Alpha-Lipoic Acid: May enhance the hypoglycemic effect of Antidiabetic Agents. Risk C: Monitor therapy

Androgens: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Risk C: Monitor therapy

Antidiabetic Agents: May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents. Risk C: Monitor therapy

Beta-Blockers (Beta1 Selective): May enhance the hypoglycemic effect of Antidiabetic Agents. Risk C: Monitor therapy

Beta-Blockers (Nonselective): May enhance the hypoglycemic effect of Insulins. Beta-Blockers (Nonselective) may diminish the therapeutic effect of Insulins. Risk C: Monitor therapy

Bortezomib: May enhance the therapeutic effect of Antidiabetic Agents. Bortezomib may diminish the therapeutic effect of Antidiabetic Agents. Risk C: Monitor therapy

Chlorprothixene: May enhance the hypoglycemic effect of Insulins. Risk C: Monitor therapy

Dipeptidyl Peptidase-IV Inhibitors: May enhance the hypoglycemic effect of Insulins. Management: Consider a decrease in insulin dose when initiating therapy with a dipeptidyl peptidase-IV inhibitor and monitor patients for hypoglycemia. Risk D: Consider therapy modification

Direct Acting Antiviral Agents (HCV): May enhance the hypoglycemic effect of Antidiabetic Agents. Risk C: Monitor therapy

Edetate CALCIUM Disodium: May enhance the hypoglycemic effect of Insulins. Risk C: Monitor therapy

Etilefrine: May diminish the therapeutic effect of Antidiabetic Agents. Risk C: Monitor therapy

Glucagon-Like Peptide-1 Agonists: May enhance the hypoglycemic effect of Insulins. Management: Consider insulin dose reductions when used in combination with glucagon-like peptide-1 agonists. Monitor patients for hypoglycemia. Risk D: Consider therapy modification

Guanethidine: May enhance the hypoglycemic effect of Antidiabetic Agents. Risk C: Monitor therapy

Herbal Products with Glucose Lowering Effects: May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents. Risk C: Monitor therapy

Hyperglycemia-Associated Agents: May diminish the therapeutic effect of Antidiabetic Agents. Risk C: Monitor therapy

Hypoglycemia-Associated Agents: May enhance the hypoglycemic effect of other Hypoglycemia-Associated Agents. Risk C: Monitor therapy

Hypoglycemia-Associated Agents: Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemia-Associated Agents. Risk C: Monitor therapy

Liraglutide: May enhance the hypoglycemic effect of Insulins. Management: Consider reducing the liraglutide dose if coadministered with insulin. Prescribing information for the Saxenda brand of liraglutide recommends a dose decrease of 50%. Monitor blood glucose for hypoglycemia. Risk D: Consider therapy modification

Macimorelin: Insulins may diminish the diagnostic effect of Macimorelin. Risk X: Avoid combination

Maitake: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Risk C: Monitor therapy

Metreleptin: May enhance the hypoglycemic effect of Insulins. Management: Insulin dosage adjustments (including potentially large decreases) may be required to minimize the risk for hypoglycemia with concurrent use of metreleptin. Monitor closely for signs and symptoms of hypoglycemia. Risk D: Consider therapy modification

Monoamine Oxidase Inhibitors: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Risk C: Monitor therapy

Pegvisomant: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Risk C: Monitor therapy

Pioglitazone: May enhance the adverse/toxic effect of Insulins. Specifically, the risk for hypoglycemia, fluid retention, and heart failure may be increased with this combination. Management: If insulin is combined with pioglitazone, consider insulin dose reductions to avoid hypoglycemia. Monitor patients for fluid retention and signs/symptoms of heart failure, and consider pioglitazone dose reduction or discontinuation if heart failure occurs Risk D: Consider therapy modification

Pramlintide: May enhance the hypoglycemic effect of Insulins. Management: Upon initiation of pramlintide, decrease mealtime insulin dose by 50% to reduce the risk of hypoglycemia. Monitor blood glucose frequently and individualize further insulin dose adjustments based on glycemic control. Risk D: Consider therapy modification

Prothionamide: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Risk C: Monitor therapy

Quinolones: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Quinolones may diminish the therapeutic effect of Agents with Blood Glucose Lowering Effects. Specifically, if an agent is being used to treat diabetes, loss of blood sugar control may occur with quinolone use. Risk C: Monitor therapy

Ritodrine: May diminish the therapeutic effect of Antidiabetic Agents. Risk C: Monitor therapy

Rosiglitazone: Insulins may enhance the adverse/toxic effect of Rosiglitazone. Specifically, the risk of fluid retention, heart failure, and hypoglycemia may be increased with this combination. Risk X: Avoid combination

Salicylates: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Risk C: Monitor therapy

Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Risk C: Monitor therapy

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: May enhance the hypoglycemic effect of Insulins. Management: Consider a decrease in insulin dose when initiating therapy with a sodium-glucose cotransporter 2 inhibitor and monitor patients for hypoglycemia. Risk D: Consider therapy modification

Thiazide and Thiazide-Like Diuretics: May diminish the therapeutic effect of Antidiabetic Agents. Risk C: Monitor therapy

Pregnancy Considerations

Based on available information, maternal use of insulin glulisine is not associated with an increased risk of adverse pregnancy outcomes (Doder 2015).

Poorly controlled diabetes during pregnancy can be associated with an increased risk of adverse maternal and fetal outcomes, including diabetic ketoacidosis, preeclampsia, spontaneous abortion, preterm delivery, delivery complications, major malformations, stillbirth, and macrosomia. To prevent adverse outcomes, prior to conception and throughout pregnancy, maternal blood glucose and HbA1c should be kept as close to target goals as possible but without causing significant hypoglycemia (ADA 2022; Blumer 2013).

Due to pregnancy-induced physiologic changes, insulin requirements tend to increase as pregnancy progresses, requiring frequent monitoring and dosage adjustments. Following delivery, insulin requirements decrease rapidly (ACOG 201 2018; ADA 2022).

Insulin is the preferred treatment of type 1 and type 2 diabetes mellitus in pregnancy, as well as gestational diabetes mellitus when pharmacologic therapy is needed (ACOG 190 2018; ACOG 201 2018; ADA 2022). Agents other than insulin glulisine are currently recommended to treat diabetes mellitus in pregnancy (ACOG 190 2018; ACOG 201 2018; Blumer 2013).

Breastfeeding Considerations

Both exogenous and endogenous insulin are present in breast milk (study not conducted with this preparation) (Whitmore 2012). Insulin is not systemically absorbed via breast milk but may provide local benefits to the infant GI tract (Anderson 2018).

Adverse events have not been reported in breastfed infants following maternal use of insulin glulisine.

Appropriate glycemic control is required for the establishment of lactation in patients with diabetes mellitus (Anderson 2018). Breastfeeding provides metabolic benefits to mothers with type 1, type 2, and gestational diabetes mellitus as well as their infants; therefore, breastfeeding is encouraged (ACOG 201 2018; ADA 2022; Blumer 2013). Breastfeeding also influences maternal glucose tolerance; close monitoring of patients treated with insulin is recommended as dose adjustments may be required (ADA 2022; Anderson 2018). A small snack before breastfeeding may help decrease the risk of hypoglycemia in patients with pregestational diabetes (ACOG 201 2018; Reader 2004). According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother.

Dietary Considerations

Individualized medical nutrition therapy (MNT) based on ADA recommendations is an integral part of therapy.

Monitoring Parameters

Diabetes mellitus: Blood glucose (individualize frequency based on treatment regimen, hypoglycemia risk, and other patient-specific factors) (ADA 2022); electrolytes; renal function; hepatic function; weight.

Gestational diabetes mellitus: Blood glucose 4 times daily (1 fasting and 3 postprandial) until well controlled, then as appropriate (ACOG 190 2018).

Hospitalized patients: In patients who are eating, monitor blood glucose before meals and at bedtime; in patients who are not eating or are receiving continuous enteral feeds, monitor blood glucose every 4 to 6 hours (ADA 2022; ES [Umpierrez 2012]). More frequent monitoring may be required in some cases (eg, recurrent hypoglycemia, changes in nutrition, medication changes affecting glycemic control) (ES [Umpierrez 2012]).

Critically ill patients receiving an IV insulin infusion: Monitor blood glucose every 1 to 2 hours; serum potassium (ADA 2022; SCCM [Jacobi 2012]; manufacturer’s labeling). Note: Arterial or venous whole blood sampling is recommended for patients in shock, on vasopressor therapy, or with severe edema, and when on a prolonged IV insulin infusion (SCCM [Jacobi 2012]).

HbA1c: Monitor at least twice yearly in patients who have stable glycemic control and are meeting treatment goals; monitor quarterly in patients in whom treatment goals have not been met, or with therapy change. Note: In patients prone to glycemic variability (eg, patients with insulin deficiency), or in patients whose HbA1c is discordant with serum glucose levels or symptoms, consider evaluating HbA1c in combination with blood glucose levels and/or a glucose management indicator (ADA 2022; KDIGO 2020).

Diabetic ketoacidosis: Frequent monitoring (eg, every 1 to 4 hours) of serum electrolytes (eg, sodium, potassium, bicarbonate, phosphate), serum glucose, anion gap, venous pH, serum BUN, serum creatinine, serum osmolality, fluid status (eg, blood pressure, fluid intake/output, signs/symptoms of dehydration or fluid overload), anion gap, and mental status. Refer also to institutional protocols (Hirsch 2021; Kitabchi 2009).

Reference Range

Recommendations for glycemic control in patients with diabetes and/or hyperglycemia:

Nonpregnant adults (AACE [Samson 2023]; ADA 2023):

HbA1c: <7% (a more aggressive [<6.5%] or less aggressive [<8%] HbA1c goal may be targeted based on patient-specific characteristics). Note : In patients using a continuous glucose monitoring system, a goal of time in range >70% with time below range <4% is recommended and is similar to a goal HbA1c <7%.

Preprandial capillary blood glucose: 80 to 130 mg/dL (SI: 4.4 to 7.2 mmol/L) (more or less stringent goals may be appropriate based on patient-specific characteristics).

Peak postprandial capillary blood glucose (~1 to 2 hours after a meal): <180 mg/dL (SI: <10 mmol/L) (more or less stringent goals may be appropriate based on patient-specific characteristics).

Older adults (≥65 years of age) (ADA 2023):

Note: Consider less strict targets in patients who are using insulin and/or insulin secretagogues (sulfonylureas, meglitinides) (ES [LeRoith 2019]).

HbA1c: <7% to 7.5% (healthy); <8% (complex/intermediate health). Note: Individualization may be appropriate based on patient and caregiver preferences and/or presence of cognitive impairment. In patients with very complex or poor health (ie, limited remaining life expectancy), consider making therapy decisions based on avoidance of hypoglycemia and symptomatic hyperglycemia rather than HbA1c level.

Preprandial capillary blood glucose: 80 to 130 mg/dL (SI: 4.4 to 7.2 mmol/L) (healthy); 90 to 150 mg/dL (SI: 5 to 8.3 mmol/L) (complex/intermediate health); 100 to 180 mg/dL (SI: 5.6 to 10 mmol/L) (very complex/poor health).

Bedtime capillary blood glucose: 80 to 180 mg/dL (SI: 4.4 to 10 mmol/L) (healthy); 100 to 180 mg/dL (SI: 5.6 to 10 mmol/L) (complex/intermediate health); 110 to 200 mg/dL (SI: 6.1 to 11.1 mmol/L) (very complex/poor health).

Pregnant patients:

HbA1c: Pregestational diabetes (type 1 or type 2) (ADA 2023):

Preconception (patients planning for pregnancy): <6.5%.

During pregnancy <6% (if can be achieved without significant hypoglycemia) or <7% if needed to prevent hypoglycemia.

Capillary blood glucose: Note: Less stringent targets may be appropriate if goals cannot be achieved without causing significant hypoglycemia (ADA 2023).

Gestational diabetes mellitus (ACOG 190 2018; ADA 2023):

Fasting: <95 mg/dL (SI: <5.3 mmol/L).

Postprandial: <140 mg/dL (SI: <7.8 mmol/L) (at 1 hour) or <120 mg/dL (SI: <6.7 mmol/L) (at 2 hours).

Pregestational diabetes mellitus (type 1 or type 2) (ADA 2023 ):

Fasting: 70 to 95 mg/dL (SI: 3.9 to 5.3 mmol/L).

Postprandial: 110 to 140 mg/dL (SI: 6.1 to 7.8 mmol/L) (at 1 hour) or 100 to 120 mg/dL (SI: 5.6 to 6.7 mmol/L) (at 2 hours).

Hospitalized adult patients (ADA 2022): Target glucose range: 140 to 180 mg/dL (SI: 7.8 to 10 mmol/L) (majority of critically ill and noncritically ill patients; <140 mg/dL (SI: <7.8 mmol/L) may be appropriate for selected patients, if it can be achieved without excessive hypoglycemia).

Perioperative care in adult patients (ADA 2022): Target glucose range during perioperative period: Consider targeting 80 to 180 mg/dL (SI: 4.4 to 10 mmol/L).

Children and adolescents:

Preprandial glucose: 70 to 130 mg/dL (SI: 3.9 to 7.2 mmol/L) (ISPAD [Dimeglio 2018]).

Postprandial glucose: 90 to 180 mg/dL (SI: 5 to 10 mmol/L) (ISPAD [Dimeglio 2018]).

Bedtime/overnight glucose: 80 to 140 mg/dL (SI: 4.4 to 7.8 mmol/L) (ISPAD [Dimeglio 2018]).

HbA1c: <7%; target should be individualized; a more stringent goal (<6.5%) may be reasonable if it can be achieved without significant hypoglycemia; less aggressive goals (<7.5% or <8%) may be appropriate in patients who cannot articulate symptoms of hypoglycemia, cannot check glucose frequently, have a history of severe hypoglycemia, or have extensive comorbid conditions (ADA 2023; ISPAD [Dimeglio 2018]).

Surgical patients (ISPAD [Jefferies 2018]):

Intraoperative: 90 to 180 mg/dL (SI: 5 to 10 mmol/L).

ICU, postsurgery: 140 to 180 mg/dL (SI: 7.8 to 10 mmol/L).

Classification of hypoglycemia (ADA 2023):

Level 1: 54 to 70 mg/dL (SI: 3 to 3.9 mmol/L); hypoglycemia alert value; initiate fast-acting carbohydrate (eg, glucose) treatment.

Level 2: <54 mg/dL (SI: <3 mmol/L); threshold for neuroglycopenic symptoms; requires immediate action.

Level 3: Hypoglycemia associated with a severe event characterized by altered mental and/or physical status requiring assistance.

Mechanism of Action

Insulin acts via specific membrane-bound receptors on target tissues to regulate metabolism of carbohydrate, protein, and fats. Target organs for insulin include the liver, skeletal muscle, and adipose tissue.

Within the liver, insulin stimulates hepatic glycogen synthesis. Insulin promotes hepatic synthesis of fatty acids, which are released into the circulation as lipoproteins. Skeletal muscle effects of insulin include increased protein synthesis and increased glycogen synthesis. Insulin stimulates lipoprotein lipase synthesis and activity; this results in hydrolysis of triglycerides into free fatty acids and storage of free fatty acids in adipocytes, thereby reducing circulating triglyceride levels (Rawla 2018; Sadur 1982; Song 2019). In addition, insulin stimulates the cellular uptake of amino acids and increases cellular permeability to several ions, including potassium, magnesium, and phosphate. By activating sodium-potassium ATPases, insulin promotes the intracellular movement of potassium.

Normally secreted by the pancreas, insulin products are manufactured for pharmacologic use through recombinant DNA technology using either E. coli or Saccharomyces cerevisiae. Insulin glulisine differs from human insulin by containing a lysine and glutamic acid at positions B3 and B29, respectively, in comparison to the asparagine and lysine found at B3 and B29 in human insulin. Insulins are categorized based on the onset, peak, and duration of effect (eg, rapid-, short-, intermediate-, and long-acting insulin). Insulin glulisine is a rapid-acting insulin analog.

Pharmacokinetics (Adult Data Unless Noted)

Note: Onset and duration of hypoglycemic effects depend upon the route of administration (absorption and onset of action are more rapid after deeper IM injections than after SUBQ), site of injection (onset and duration are progressively slower with SUBQ injection into the abdomen, arm, buttock, or thigh respectively), volume and concentration of injection, and the preparation administered. Rate of absorption, onset, and duration of activity may be affected by exercise, presence of lipodystrophy, local blood supply, and/or temperature.

Onset of action: 0.2 to 0.5 hours.

Peak effect: 1.6 to 2.8 hours.

Duration: 3 to 4 hours.

Distribution: IV: 13 L.

Bioavailability: SUBQ: ~70%.

Half-life elimination:

IV: 13 minutes.

SUBQ: 42 minutes.

Time to peak, plasma: 60 minutes (range: 40 to 120 minutes).

Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)

Altered kidney function: Insulin clearance may be reduced in patients with impaired renal function.

Obesity: Tmax occurs faster and Cmax is greater with insulin glulisine compared with regular human insulin in obese patients.

Brand Names: International
International Brand Names by Country
For country code abbreviations (show table)

  • (AE) United Arab Emirates: Apidra;
  • (AT) Austria: Apidra;
  • (AU) Australia: Apidra;
  • (BD) Bangladesh: Apidra;
  • (BE) Belgium: Apidra;
  • (BG) Bulgaria: Apidra | Apidra solostar;
  • (BR) Brazil: Apidra;
  • (CL) Chile: Apidra;
  • (CO) Colombia: Apidra;
  • (CZ) Czech Republic: Apidra;
  • (DE) Germany: Apidra;
  • (DO) Dominican Republic: Apidra;
  • (EC) Ecuador: Apidra;
  • (EE) Estonia: Apidra;
  • (EG) Egypt: Apidra;
  • (ES) Spain: Apidra;
  • (ET) Ethiopia: Apidra;
  • (FI) Finland: Apidra;
  • (FR) France: Apidra | Insuline glulisine;
  • (GB) United Kingdom: Apidra;
  • (GR) Greece: Apidra;
  • (HK) Hong Kong: Apidra;
  • (HR) Croatia: Apidra | Apidra solostar;
  • (HU) Hungary: Apidra;
  • (ID) Indonesia: Apidra;
  • (IE) Ireland: Apidra;
  • (IL) Israel: Apidra;
  • (IN) India: Apidra;
  • (IT) Italy: Apidra;
  • (JO) Jordan: Apidra solostar;
  • (JP) Japan: Apidra;
  • (KE) Kenya: Apidra solostar;
  • (KR) Korea, Republic of: Apidra | Apidra solostar;
  • (KW) Kuwait: Apidra | Apidra solostar;
  • (LB) Lebanon: Apidra | Apidra solostar;
  • (LT) Lithuania: Apidra;
  • (LU) Luxembourg: Apidra;
  • (LV) Latvia: Apidra;
  • (MA) Morocco: Apidra;
  • (MX) Mexico: Apidra | Shorant;
  • (MY) Malaysia: Apidra solostar;
  • (NL) Netherlands: Apidra;
  • (NO) Norway: Apidra;
  • (NZ) New Zealand: Apidra;
  • (PE) Peru: Apidra;
  • (PH) Philippines: Apidra;
  • (PL) Poland: Apidra;
  • (PR) Puerto Rico: Apidra solostar;
  • (PT) Portugal: Apidra;
  • (PY) Paraguay: Apidra;
  • (QA) Qatar: Apidra | Apidra SoloStar;
  • (RO) Romania: Apidra;
  • (RU) Russian Federation: Apidra | Apidra solostar;
  • (SA) Saudi Arabia: Apidra;
  • (SE) Sweden: Apidra;
  • (SG) Singapore: Apidra;
  • (SI) Slovenia: Apidra;
  • (SK) Slovakia: Apidra;
  • (TH) Thailand: Apidra;
  • (TN) Tunisia: Apidra solostar;
  • (TR) Turkey: Apidra;
  • (TW) Taiwan: Apidra;
  • (UA) Ukraine: Apidra;
  • (UY) Uruguay: Apidra;
  • (VE) Venezuela, Bolivarian Republic of: Apidra solostar;
  • (ZA) South Africa: Apidra
  1. 2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023;71(7):2052-2081. doi:10.1111/jgs.18372 [PubMed 37139824]
  2. American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins—Obstetrics. Practice Bulletin No. 190: Gestational diabetes mellitus. Obstet Gynecol. 2018;131(2):e49-e64. [PubMed 29370047]
  3. American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins-Obstetrics. Practice Bulletin No. 201: Pregestational diabetes mellitus. Obstet Gynecol. 2018;132(6):e228-e248. doi:10.1097/AOG.0000000000002960 [PubMed 30461693]
  4. American Diabetes Association (ADA). Standards of care in diabetes–2023. Diabetes Care. 2023;45(suppl 1):S1-S291. https://diabetesjournals.org/care/issue/46/Supplement_1. Accessed February 6, 2023.
  5. American Diabetes Association (ADA). Standards of medical care in diabetes–2020. Diabetes Care. 2020;43(suppl 1):S1-S212. https://care.diabetesjournals.org/content/43/Supplement_1. Accessed January 22, 2020.
  6. American Diabetes Association (ADA). Standards of medical care in diabetes–2022. Diabetes Care. 2022;45(suppl 1):S1-S255. https://diabetesjournals.org/care/issue/45/Supplement_1. Accessed September 19, 2022.
  7. Anderson PO. Treating diabetes during breastfeeding. Breastfeed Med. 2018;13(4):237-239. doi:10.1089/bfm.2018.0036 [PubMed 29608329]
  8. Apidra (insulin glulisine) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; November 2019.
  9. Apidra (insulin glulisine) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; November 2022.
  10. Apovian CM, Aronne LJ, Bessesen DH, et al; Endocrine Society. Pharmacological management of obesity: an endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(2):342‐362. doi:10.1210/jc.2014-3415 [PubMed 25590212]
  11. Arslanian S, Bacha F, Grey M, Marcus MD, White NH, Zeitler P. Evaluation and management of youth-onset type 2 diabetes: a position statement by the American Diabetes Association. Diabetes Care. 2018;41(12):2648-2668. [PubMed 30425094]
  12. Beck JK, Cogen FR. Outpatient Management of Pediatric Type 1 Diabetes. J Pediatr Pharmacol Ther. 2015;20(5):344-357. doi: 10.5863/1551-6776-20.5.344 [PubMed 26472948]
  13. Blumer I, Hadar E, Hadden DR, et al. Diabetes and pregnancy: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2013;98(11):4227-4249. [PubMed 24194617]
  14. Cardoso L, Vicente N, Rodrigues D, Gomes L, Carrilho F. Controversies in the management of hyperglycaemic emergencies in adults with diabetes. Metabolism. 2017;68:43-54. doi:10.1016/j.metabol.2016.11.010 [PubMed 28183452]
  15. Centers for Disease Control and Prevention. CDC clinical reminder: insulin pens must never be used for more than one person. Centers for Disease Control and Prevention Web site. http://www.cdc.gov/injectionsafety/clinical-reminders/insulin-pens.html. Updated January 5, 2012. Accessed January 9, 2012.
  16. Chiang JL, Kirkman MS, Laffel LM, et al; Type 1 Diabetes Sourcebook Authors. Type 1 diabetes through the life span: a position statement of the American Diabetes Association. Diabetes Care. 2014;37(7):2034-54. doi:10.2337/dc14-1140 [PubMed 24935775]
  17. Clement S, Braithwaite SS, Magee MF, et al; American Diabetes Association Diabetes in Hospitals Writing Committee. Management of diabetes and hyperglycemia in hospitals. Diabetes Care. 2004;27(2):553-591. doi:10.2337/diacare.27.2.553 [PubMed 14747243]
  18. Copeland KC, Silverstein J, Moore KR, et al; American Academy of Pediatrics. Management of newly diagnosed type 2 diabetes mellitus (T2DM) in children and adolescents. Pediatrics. 2013;131(2):364-382. doi:10.1542/peds.2012-3494 [PubMed 23359574]
  19. Cruijsen M, Koehestani P, Huttjes S, Leenders K, Janssen I, de Boer H. Perioperative glycaemic control in insulin-treated type 2 diabetes patients undergoing gastric bypass surgery. Neth J Med. 2014;72(4):202‐209. [PubMed 24829176]
  20. Danne T, Phillip M, Buckingham BA, et al. ISPAD Clinical Practice Consensus Guidelines 2018: Insulin treatment in children and adolescents with diabetes. Pediatr Diabetes. 2018;19(suppl 27):115-135. doi:10.1111/pedi.12718 [PubMed 29999222]
  21. Davies MJ, D'Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41(12):2669-2701. doi:10.2337/dci18-0033 [PubMed 30291106]
  22. de Bock M, Codner E, Craig ME, et al. ISPAD Clinical Practice Consensus Guidelines 2022: Glycemic targets and glucose monitoring for children, adolescents, and young people with diabetes. Pediatr Diabetes. 2022;23(8):1270-1276. doi:10.1111/pedi.13455 [PubMed 36537523]
  23. DiMeglio LA, Acerini CL, Codner E, et al. ISPAD Clinical Practice Consensus Guidelines 2018: Glycemic control targets and glucose monitoring for children, adolescents, and young adults with diabetes. Pediatr Diabetes. 2018;19(suppl 27):105‐114. doi:10.1111/pedi.12737 [PubMed 30058221]
  24. Doder Z, Vanechanos D, Oster M, Landgraf W, Lin S. Insulin glulisine in pregnancy - experience from clinical trials and post-marketing surveillance. Eur Endocrinol. 2015;11(1):17-20. [PubMed 29632561]
  25. Garber AJ, Handelsman Y, Grunberger G, et al. Consensus Statement by the American Association of Clinical Endocrinologists snd American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2020 executive summary. Endocr Pract. 2020;26(1):107‐139. doi:10.4158/CS-2019-0472 [PubMed 32022600]
  26. Gianchandani RY, Iyengar JL, Butler SO, et al. Inpatient diabetes guideline for adult non-critically ill patients. Michigan Medicine, University of Michigan; May 2020. [PubMed 32931166]
  27. Greenwood BC, Chesnick MA, Szumita PM, Belisle C, Cotugno M. Stability of regular human insulin extemporaneously prepared in 0.9% sodium chloride in a polyvinyl chloride bag. Hosp Pharm. 2012;47(5):367-370.
  28. Handelsman Y, Bloomgarden ZT, Grunberger G, et al. American Association of Clinical Endocrinologists and American College of Endocrinology - clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015. Endocr Pract. 2015;21(suppl 1):1-87. doi:10.4158/EP15672.GL https://journals.aace.com/doi/pdf/10.4158/EP15672.GLSUPPL. Accessed April 22, 2020. [PubMed 25869408]
  29. Hirsch IB, Emmett M. Diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults: treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. https://www.uptodate.com. Accessed September 27, 2021.
  30. Hirsch JI, Fratkin MJ, Wood JH, Thomas RB. Clinical significance of insulin adsorption by polyvinyl chloride infusion systems. Am J Hosp Pharm. 1977;34(6):583-588. [PubMed 406784]
  31. Hirsch JI, Wood JH, Thomas RB. Insulin adsorption to polyolefin infusion bottles and polyvinyl chloride administration sets. Am J Hosp Pharm. 1981;38(7):995-997. [PubMed 7020415]
  32. Inzucchi SE. Diabetes facts and guidelines. https://medicine.yale.edu/intmed/drc/diabetescenter/living/50135_Yale%20National%20F_102165_284_13584_v1.pdf. Published 2011. Accessed January 12, 2021.
  33. Jacobi J, Bircher N, Krinsley J, et al. Guidelines for the use of an insulin infusion for the management of hyperglycemia in critically ill patients. Crit Care Med. 2012;40(12):3251-3276. doi:10.1097/CCM.0b013e3182653269 [PubMed 23164767]
  34. Jefferies C, Rhodes E, Rachmiel M, et al. ISPAD clinical practice consensus guidelines 2018: management of children and adolescents with diabetes requiring surgery. Pediatr Diabetes. 2018;19(suppl 27):227-236. doi:10.1111/pedi.12733 [PubMed 30039617]
  35. Kapellen T, Agwu JC, Martin L, et al. ISPAD clinical practice consensus guidelines 2022: management of children and adolescents with diabetes requiring surgery. Pediatr Diabetes. 2022;23(8):1468-1477. doi:10.1111/pedi.13446 [PubMed 36537521]
  36. Kidney Disease: Improving Global Outcomes (KDIGO) diabetes work group. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2020;98(4S):S1-S115. doi:10.1016/j.kint.2020.06.019 [PubMed 32998798]
  37. Kirkman M, Briscoe VJ, Clark N, et al, "Diabetes in Older Adults: A Consensus Report," J Am Geriatr Soc, 2012; doi: 10.1111/jgs.12035. [PubMed 23106132]
  38. Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN. Hyperglycemic crises in adult patients with diabetes. Diabetes Care. 2009;32(7):1335-1343. doi:10.2337/dc09-9032 [PubMed 19564476]
  39. Kitabchi AE, Umpierrez GE, Murphy MB, et al, "Hyperglycemic Crises in Diabetes,” Diabetes Care, 2004, 27(Suppl 1): 94-102. [PubMed 14693938]
  40. Korner J, Inabnet W, Febres G, et al. Prospective study of gut hormone and metabolic changes after adjustable gastric banding and Roux-en-Y gastric bypass. Int J Obes (Lond). 2009;33(7):786‐795. doi:10.1038/ijo.2009.79 [PubMed 19417773]
  41. Leung V, Ragbir-Toolsie K. Perioperative management of patients with diabetes. Health Serv Insights. Published online November 15, 2017. doi:10.1177/1178632917735075 [PubMed 29162977]
  42. LeRoith D, Biessels GJ, Braithwaite SS, et al. Treatment of diabetes in older adults: an Endocrine Society* Clinical Practice Guideline. J Clin Endocrinol Metab. 2019;104(5):1520‐1574. doi:10.1210/jc.2019-00198 [PubMed 30903688]
  43. Magaji V, Johnston JM. Inpatient management of hyperglycemia and diabetes. Clinical Diabetes. 2011;29(1):3-9. doi:10.2337/diaclin.29.1.3
  44. Mechanick JI, Apovian C, Brethauer S, et al. Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures - 2019 update: cosponsored by American Association of Clinical Endocrinologists/American College of Endocrinology, the Obesity Society, American Society for Metabolic & Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists. Surg Obes Relat Dis. 2020;16(2):175-247. doi:10.1016/j.soard.2019.10.025 [PubMed 31917200]
  45. Moghissi ES, Korytkowski MT, DiNardo M, et al, “American Association of Clinical Endocrinologists and American Diabetes Association Consensus Statement on Inpatient Glycemic Control,” Endocr Pract, 2009, 15(4):353-69. [PubMed 19454396]
  46. NICE-SUGAR Study Investigators, Finfer S, Chittock DR, et al, “Intensive Versus Conventional Glucose Control in Critically Ill Patients,” N Engl J Med, 2009, 360(13):1283-97. [PubMed 19318384 ]
  47. Peterli R, Steinert RE, Woelnerhanssen B, et al. Metabolic and hormonal changes after laparoscopic Roux-en-Y gastric bypass and sleeve gastrectomy: a randomized, prospective trial. Obes Surg. 2012;22(5):740‐748. doi:10.1007/s11695-012-0622-3 [PubMed 22354457]
  48. Peters AP, Laffel L, eds. Type 1 Diabetes Sourcebook. American Diabetes Association; 2013.
  49. Rawla P, Sunkara T, Thandra KC, Gaduputi V. Hypertriglyceridemia-induced pancreatitis: updated review of current treatment and preventive strategies. Clin J Gastroenterol. 2018;11(6):441-448. doi:10.1007/s12328-018-0881-1 [PubMed 29923163]
  50. Rawla P, Vellipuram AR, Bandaru SS, Pradeep Raj J. Euglycemic diabetic ketoacidosis: a diagnostic and therapeutic dilemma. Endocrinol Diabetes Metab Case Rep. 2017;2017:17-0081. doi:10.1530/EDM-17-0081 [PubMed 28924481]
  51. Reader D, Franz MJ. Lactation, diabetes, and nutrition recommendations. Curr Diab Rep. 2004;4(5):370-376. [PubMed 15461903]
  52. Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med. 2017;43(3):304-377. doi: 10.1007/s00134-017-4683-6. [PubMed 28101605]
  53. Rocchio MA, Belisle CD, Greenwood BC, Cotugno MC, Szumita PM. Evaluation of the maximum beyond-use-date stability of regular human insulin extemporaneously prepared in 0.9% sodium chloride in a polyvinyl chloride bag. Diabetes Metab Syndr Obes. 2013;6:389-392. [PubMed 24143117]
  54. Sadur CN, Eckel RH. Insulin stimulation of adipose tissue lipoprotein lipase. Use of the euglycemic clamp technique. J Clin Invest. 1982;69(5):1119-1125. doi:10.1172/jci110547 [PubMed 7040473]
  55. Samson SL, Vellanki P, Blonde L, et al. American Association of Clinical Endocrinology consensus statement: comprehensive type 2 diabetes management algorithm – 2023 update. Endocr Pract. 2023;29(5):305-340. doi:10.1016/j.eprac.2023.02.001 [PubMed 37150579]
  56. Shah AS, Zeitler PS, Wong J, et al. ISPAD clinical practice consensus guidelines 2022: type 2 diabetes in children and adolescents. Pediatr Diabetes. 2022;23(7):872-902. doi:10.1111/pedi.13409 [PubMed 36161685]
  57. Silverstein J, Klingensmith G, Copeland K, et al. Care of children and adolescents with type 1 diabetes: a statement of the American Diabetes Association. Diabetes Care. 2005;28(1):186-212. [PubMed 15616254]
  58. Song X, Shi D, Cui Q, et al. Intensive insulin therapy versus plasmapheresis in the management of hypertriglyceridemia-induced acute pancreatitis (Bi-TPAI trial): study protocol for a randomized controlled trial. Trials. 2019;20(1):365. doi:10.1186/s13063-019-3498-x [PubMed 31215460]
  59. Sundberg F, Barnard K, Cato A, et al. ISPAD Guidelines. Managing diabetes in preschool children. Pediatr Diabetes. 2017;18(7):499-517. doi: 10.1111/pedi.12554 [PubMed 28726299]
  60. Thompson CD, Vital-Carona J, Faustino EV. The effect of tubing dwell time on insulin adsorption during intravenous insulin infusions. Diabetes Technol Ther. 2012;14(10):912-916. [PubMed 22746979]
  61. Umpierrez GE, Hellman R, Korytkowski MT, et al; Endocrine Society. Management of hyperglycemia in hospitalized patients in non-critical care setting: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2012;97(1):16-38. doi:10.1210/jc.2011-2098 [PubMed 22223765]
  62. Umpierrez GE, Jones S, Smiley D, et al. Insulin analogs versus human insulin in the treatment of patients with diabetic ketoacidosis: a randomized controlled trial. Diabetes Care. 2009;32(7):1164-1169. [PubMed 19366972]
  63. Wexler DJ. Insulin therapy in type 2 diabetes mellitus. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. https://www.uptodate.com. Accessed September 19, 2022.
  64. Whitmore TJ, Trengove NJ, Graham DF, Hartmann PE. Analysis of insulin in human breast milk in mothers with type 1 and type 2 diabetes mellitus. Int J Endocrinol. 2012;2012:296368. [PubMed 22500167]
  65. Wiener RS, Wiener DC, Larson RJ. Benefits and risks of tight glucose control in critically ill adults: a meta-analysis. JAMA. 2008;300(8):933-944. [PubMed 18728267]
  66. Zeitler P, Arslanian S, Fu J, Pinhas-Hamiel O, et al. ISPAD Clinical Practice Consensus Guidelines 2018: Type 2 diabetes mellitus in youth. Pediatr Diabetes. 2018;19(suppl 27):28-46. doi: 10.1111/pedi.12719. [PubMed 29999228]
Topic 9024 Version 269.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟